Welcome to our dedicated page for Ventas SEC filings (Ticker: VTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Ventas’ filings can feel like sorting through hundreds of pages on rent escalators, triple-net lease covenants, and senior-housing occupancy rates. If you’ve ever asked, “Where’s the dividend guidance hidden in Ventas’ annual report 10-K?” or hunted for Ventas insider trading Form 4 transactions, you know the challenge.
Stock Titan solves it. Our platform ingests every Ventas quarterly earnings report 10-Q filing, 8-K, and proxy in real time, then delivers plain-English, AI-powered summaries. Need Ventas Form 4 insider transactions real-time? Get instant alerts. Trying to compare deferred rent trends quarter over quarter? Our AI highlights the numbers and adds context so you’re understanding Ventas SEC documents with AI instead of decoding footnotes.
You’ll find more than a list of forms. We connect each document to what matters for a healthcare REIT: the 10-K section that forecasts SHOP margins, the 8-K paragraph announcing operator restructurings (Ventas 8-K material events explained), or the Ventas proxy statement executive compensation table that details incentive targets. Whether you’re scanning a Ventas annual report 10-K simplified for dividend coverage or running a quick Ventas earnings report filing analysis, the insights are ready in minutes—no spreadsheet gymnastics required. Monitor Ventas executive stock transactions Form 4, track payout ratios, and see AI-generated red-flag alerts across ALL filing types the moment they hit EDGAR.
Ventas, Inc. (VTR) Form 144 notice reports a proposed sale of common stock by an insider and recent related sales. The filer indicates a broker-assisted sale of 10,322 shares valued at $699,863.18 to occur on 09/02/2025 on the NYSE. The filing states the shares were acquired the same day by exercise of employee stock options from Ventas, Inc.
The filing also discloses five common-stock sales by the same person during July–August 2025 totaling 31,990 shares with aggregate gross proceeds listed per sale (largest single prior sale: 14,753 shares for $967,822.54). Total shares outstanding is shown as 454,471,192, which provides context for the size of the proposed sale relative to the company.
Reporting person: Robert F. Probst, EVP and CFO of Ventas, Inc. (VTR). Transaction date: 08/04/2025; Form filed: 08/06/2025.
Actions: Probst exercised 29,691 fully vested stock options at an exercise price of $65.45 and sold 29,691 underlying shares pursuant to a Rule 10b5-1 trading plan entered on 02/19/2025. The shares were sold in multiple transactions at prices ranging $68.45–$68.5563 with a weighted average sale price of $68.4917.
Post-transaction position: Beneficial ownership reported as 168,364 shares held directly; 33,591 unexercised options remain (expiration 05/04/2026).
Form 4 Overview: On 07/17/2025, Ventas, Inc. (VTR) director Sumit Roy automatically received two common-stock equivalent grants generated by dividend-equivalent credits: 49.07 units under the Non-Employee Directors’ Cash Compensation Deferral Plan and 78.961 units under the Non-Employee Directors’ Equity Award Deferral Program, totaling 128.031 shares. The grants were valued at the 07/17/2025 closing price of $65.37 and are payable solely in common stock per the respective plan terms.
Following the credits, Roy’s direct beneficial ownership rose to 20,770.297 shares. No open-market transactions, sales, or derivative exercises were reported, and Table II shows no derivative positions. Because the award is routine, non-cash and represents a de-minimis percentage of Ventas’ outstanding shares, it is unlikely to have an immediate impact on share supply or market sentiment.
FAQ
What is the current stock price of Ventas (VTR)?
What is the market cap of Ventas (VTR)?
